Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Alcobra Reports Adult ADHD Drug Failed Late-Stage Study

By Ryan Bushey | January 18, 2017

Alcobra, a pharmaceutical company based in Israel, announced on Tuesday that its experimental drug for treating attention deficit hyperactivity disorder (ADHD) missed its primary endpoint in a second Phase 3 clinical trial.

The drug is called Metadoxine Extended Release (MDX), which was being tested as therapy for adults with ADHD in a study featuring 283 patients.

Results from the trial had failed to produce a statistically significant benefit from placebo in helping patients cope with the symptoms forcing the company to end the ADHD development program.

“We are exceedingly disappointed with these top-line results. In the coming weeks, the company intends to review the full data set from MEASURE. Consequently, we will evaluate our options and communicate our strategic plan to investors,” said Alcobra’s President & CEO Yaron Daniely, Ph.D., in a statement.

MDX has traversed a difficult path during the research and development process.

The Food and Drug Administration placed a full clinical hold on the drug in September 2016 after reviewing preclinical data that indicated “adverse neurological findings,” showing potentially damaging effects on peripheral nerve function in animal studies,according to FierceBiotech.

The full clinical hold became partial last month, but the primary concern with this therapy was the efficacy of it instead of safety concerns during human trials. MDX was well tolerated in this recent evaluation as well.

Essentially, the hope was that MDX could give Alcobra an advantage in the growing ADHD treatment market. A report from research and consulting firm GlobalData predicts this market could be a lucrative opportunity for drugmakers who create new effective treatment options.

Alcobra may continue developing MDX for other treatment options such as Fragile X syndrome, which is a rare genetic condition that can cause intellectual disability.

The company’s share price is currently down almost 50 percent in mid-day trading.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE